IMANX Mutual Fund

NAV$22.68

Fund Essentials - as of Feb 28, 2026

Net Assets
$260M
Expense Ratio
1.00%
Dividend Yield (Current)
0.10%
Holdings
112
Inception Date
Jun 30, 2000
Fund Family
Allied Asset Advisors
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Annually

Performance

YTD+20.18%
1 Year+39.17%
3 Year+22.09%
5 Year+14.94%
10 Year+19.14%

Asset Allocation

Stocks: 100.00%

Price Chart (6M)

Loading chart data...

Top Holdings

View All →
TickerNameWeight
AAPLApple Inc7.73%
TSM:TWTaiwan Semi. Mfg. Co., Adr7.64%
NVDANvidia Corp6.13%
GOOGAlphabet Inc series C5.43%
MSFTMicrosoft Corp 4.100 Feb 06 375.33%
Top 10 Concentration: 47.51%Report Date: Feb 28, 2026
Download all 112 holdings for IMANX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
0.10%
Frequency
Annually
Latest Distribution
$3.01
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO
See how IMANX ranks against its peers
Category rank, peer-average returns and outperformance, updated daily.
$49$29/mo
Claim the $29 launch price
First 500 subscribers, then $49/mo. Cancel anytime. From MarketXLS, trusted since 2014.

IMANX Mutual Fund Overview

IMANX Mutual Fund (Iman Fund Class K) is managed by Allied Asset Advisors with $259.7M in net assets. IMANX expense ratio is 1.00%, holding 112 positions across sectors including Information Technology, Health Care, Communication Services. Inception date: 2000-06-30.

IMANX performance shows a YTD return of 20.18%. The 1-year return is 39.17% and the 5-year return is 14.94%. IMANX dividend yield stands at 0.10%, paid annually.

IMANX top holdings include Apple Inc (7.7%), Taiwan Semi. Mfg. Co., Adr (7.6%), Nvidia Corp (6.1%), Alphabet Inc series C (5.4%), Microsoft Corp 4.100 Feb 06 37 (5.3%). View all IMANX holdings, sector breakdown, or dividend history.

IMANX can be compared against other funds using the overlap calculator or side-by-side comparison tool. IMANX alternatives are available via the screener, along with tax-loss harvesting opportunities.